Related Experiment Videos
[Treatment of ischemic myocardiopathy]
1Service de cardiologie B, Centre hospitalier universitaire de Nancy-Brabois, Vandoeuvre-les-Nancy.
Insights
Managing ischaemic myocardiopathy involves controlling risk factors and using antiplatelet therapy. Treatment also includes antianginal drugs, heart failure medications like ACE inhibitors and diuretics, and possibly beta-blockers or revascularization.
Area of Science:
- Cardiology
- Internal Medicine
Context:
- Ischaemic myocardiopathy is a significant cause of heart failure.
- Effective management requires addressing coronary risk factors and myocardial ischaemia.
Purpose:
- To outline the recommended medical and interventional therapies for ischaemic myocardiopathy.
- To guide clinical decision-making in the treatment of this condition.
Summary:
- Management includes risk factor control, antiplatelet therapy, and antianginal agents if ischaemia is present.
- For heart failure, angiotensin-converting enzyme inhibitors and diuretics are recommended, with beta-blockers considered based on symptoms.
- Asymptomatic patients may benefit from angiotensin-converting enzyme inhibitors, and coronary revascularization is an option for refractory cases.
Impact:
- Optimized treatment strategies can improve outcomes for patients with ischaemic myocardiopathy.
- This guidance supports clinicians in providing evidence-based care for heart failure due to coronary artery disease.
Abstract:
Ischaemic myocardiopathy mandates the control of coronary risk factors and the administration of antiplatelet therapy. If myocardial ischaemia exists, an antianginal treatment will be prescribed. In case of heart failure, the association of an angiotensin-converting enzyme inhibitor and diuretics is required. A beta-blocker, especially at low dose, should be discussed according to the symptoms. When ischaemic cardiomyopathy is asymptomatic, an angiotensin-converting enzyme inhibitors is also likely to benefit the patient. Coronary revascularization may be indicated according to the importance of both residual ischaemia and resistance to medical therapy.